Prime Medicine (PRME) Return on Capital Employed (2022 - 2026)

Prime Medicine has reported Return on Capital Employed for 5 years, with the latest figure at 73.15% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 99.0% year-over-year to 73.15%; the trailing twelve-month figure through Mar 2026 stood at 73.15% (up 99.0% YoY), and the FY2025 full-year result was 73.71%, up 2376.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 73.15%, down from 63.83% in the prior quarter.
• The five-year high for Return on Capital Employed was 43.42% in Q1 2023, with the low at 127.94% in Q4 2023.
• Historically, Return on Capital Employed has averaged 74.79% across 5 years, with a median of 73.65% in 2025.
• Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 8330 bps — and 2024, when it jumped 5489 bps.
• Prime Medicine's Return on Capital Employed stood at 44.64% in 2022, then tumbled by 187 bps to 127.94% in 2023, then jumped by 43 bps to 73.04% in 2024, then rose by 13 bps to 63.83% in 2025, then dropped by 15 bps to 73.15% in 2026.
• The last three Return on Capital Employed figures came in at 73.15% (Q1 2026), 63.83% (Q4 2025), and 68.68% (Q3 2025), per Business Quant data.